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Nine rhesus macaques in groups of three received a single dose of the injectable progestin-based contraceptive Depo-Provera 5 weeks prior to
challenge intravaginally with varying doses of a mixture of the pathogenic CXCR4 (X4)-SHIVSF33A and CCR5 (R5)-SHIVSF162P3 isolates. As
controls, seven Depo-naive animals were inoculated once with a high-dose of the mixed inoculum. Irrespective of inoculum dose, acute viremia
was higher in the Depo-treated than in the Depo-naive animals. Further, genetic complexity of the replicating virus was greater and replication of
the X4 virus was favored in dually infected animals treated with Depo-Provera. Analysis of cellular immune responses revealed slower response
rates in virus-specific IFN-γ production to SIV Gag in the Depo-treated macaques. The immunosuppressive effect of Depo-Provera on mounting
an antiviral cellular immune response may account for the increase viral burden and diversity, and the predominance of X4 virus replication in
SHIV infected macaques that were administered the progestin-based contraceptive.
© 2006 Elsevier Inc. All rights reserved.Keywords: Hormonal contraceptive use; SHIV susceptibility; ReplicationIntroduction
The role of sexual hormones in HIV infection remains
unclear. Female sexual hormone-induced changes may alter the
infectiousness of the virus and/or susceptibility of the host to
HIV infection (Baeten and Overbaugh, 2003; Lavreys et al.,
2004b; Martin et al., 1998). In support of this notion, the use of
hormonal contraception was strongly associated with HIV-1
shedding in cervical secretions (Clemetson et al., 1993; Mostad
et al., 1997), and a trend for an association between the use of
high-dose oral contraceptives and HIV-1 acquisition has been
reported (Guimaraes et al., 1995; Lavreys et al., 2004b; Martin
et al., 1998; Ungchusak et al., 1996; Wang et al., 1999).
Moreover, a recent large prospective study in Uganda reported
an increased risk of incident HIV infection during pregnancy
(Gray et al., 2005). Behavioral factors appeared to have little
effect, leading to the suggestion that biological factors such as⁎ Corresponding author. Fax: +1 212 448 5158.
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responses have an important role. Further, women who became
infected with HIV through the vaginal route while taking the
injectable contraceptive depomedroxyprogesterone acetate
(Depo-Provera, DMPA) had more viral variants and higher
viral loads than women not receiving a contraceptive agent
(Lavreys et al., 2004a; Sagar et al., 2004). Given that hormonal
contraception is an effective, affordable birth control method
that is in widespread use, information on its effects in HIV-1
transmission and disease will not only be of significant public
health importance, but will have implications for the design and
testing of novel approaches for HIV prevention and intervention
in women.
Because of the similarities existing between rhesus
macaques (RM) and humans at the physiological and
immunological levels, simian immunodeficiency virus (SIV)
and simian-human immunodeficiency virus (SHIV) infection
of these animals represent excellent models to study HIV-1
transmission and pathogenesis in a controlled manner (Miller,
1994). In previous transmission studies, it was established that
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and SHIV infection (Marx et al., 1996; Mascola et al., 2000),
with elevated plasma viral RNA during the acute stage of
infection compared to untreated controls (Abel et al., 2004;
Marx et al., 1996). This enhancement of SIV/SHIV transmis-
sion and infection in DMPA treated macaques was attributed
to the thinning of the vaginal epithelium (Hild-Petito et al.,
1998; Marx et al., 1996; Smith et al., 2000), but possible
effects of the contraceptive hormone on the vaginal microen-
vironment and/or host immunity could not be excluded
(Grossman, 1984; Hillier and Lau, 1997).
The cellular and molecular mechanisms by which sex
steroid hormones modulate immune responses are not well
understood (Beagley and Gockel, 2003; Brabin, 2002; Gross-
man, 1984; Paavonen, 1994; Wira, 1999). Upregulation of the
CXCR4 and CCR5 chemokine receptors on CD4+ T cells in
the cervical epithelium of healthy women has been reported to
be associated with oral contraceptive use (Prakash et al.,
2002), which might enhance HIV-1 susceptibility. Progester-
one also affects lymphocyte migration and proliferation in the
female genital tract (Inoue et al., 1996; Whitelaw and Croy,
1996; Zang et al., 2002) and inhibits a number of
immunological responses, including macrophage phagocyto-
sis, natural killer cell activity, cytotoxic T-cell (CTL) activity,
T cell proliferation and the secretion of Th1-type cytokines
that are generally associated with an effective CTL response
(Clemens et al., 1979; Hunt et al., 1998; Mannel et al., 1990;
Piccinni et al., 1995; White et al., 1997; Yeaman et al., 2003).
Similar immunomodulatory effects of hormone replacements
have been reported in nonhuman primates (Attanasio et al.,
2002; Keller et al., 2001).
We have used infection of RM with pathogenic X4-
SHIVSF33A and R5-SHIVSF162P3 to address the impact of
coreceptor usage on virus transmission and induced disease.
We found that whereas infection with X4-SHIVSF33A caused
severe and sustained peripheral CD4+ T cell loss, infection
with R5-SHIVF162P3 resulted in transient loss of CD4+ T cells
in peripheral blood and lymph nodes, but dramatic depletion
in gut-associated lymphoid tissues (Harouse et al., 1999). In a
more recent study, we showed that while both viruses were
simultaneously transmitted from mixed inocula, replication of
R5-SHIVSF162P3 predominated following acute infection, after
the appearance of host immune responses (Harouse et al.,
2003). Upon CD8+ T cell depletion in the dually infected
macaques at the time of R5 dominance, the X4 virus
emerged, suggesting that replication of X4-SHIVSF33A is
more susceptible to the control of antiviral cellular immune
response.
In the present study, macaques were infected with mixed
inocula of X4-SHIVSF33A and R5-SHIVSF162P3 in the absence
or presence of Depo-Provera to assess the effect of hormonal
contraceptive use on the virologic and immunologic outcomes
of SHIV infection. Co-infection with X4 and R5 viruses was
used to mimic many natural infections in humans (Cornelissen
et al., 1995; Groenink et al., 1991; Michael et al., 1998; Pratt
et al., 1995; Sheppard et al., 2002). We examined whether the
viral load, complexity of the transmitted viruses and genotypeof the replicating viruses could be modulated with use of the
injectable progestin-based contraceptive, and investigated the
underlying mechanistic basis for such alterations.
Results
Depo-Provera treatment increases acute viral burden
The levels of plasma viremia and CD4+ T cell count in
Depo-Provera treated and untreated SHIV-infected macaques
were analyzed. The three animals in group A did not receive
hormonal treatment and were inoculated once with a high-
dose inoculum containing ∼6000 TCID50 each of X4-
SHIVSF33A and R5-SHIVSF162P3 to assure high infection
rates. Macaques in groups B, C and D were given a single
intramuscular dose of 30 mg Depo-Provera 5 weeks prior to
inoculation. These latter groups of three animals each were
used in a prior study to determine the dose required to
achieve 100% vaginal transmission in Depo-treated macaques
(Boadi et al., 2005). Group B animals received 1250 TCID50
each of the same SHIV virus stocks as animals in group A
(a total of 2500 TCID50), and macaques in Groups C and D
were inoculated with mixtures containing 250 and 50 TCID50
of each virus, respectively. To increase the statistical power of
the analysis, data from four historic Depo-naive animals
dually infected with 104 TCID50 of mixed inoculum were
included (Harouse et al., 2003). Results over an observation
period of 12 weeks, a time needed for a stable viral “set-
point” to be established (Mellors et al., 1996), are shown in
Fig. 1.
All Depo-treated and Depo-naive animals were infected.
Plasma viremia peaked at 3 weeks post-infection (wpi) to
∼108 RNA copies/ml in all three groups of Depo-treated
animals. In contrast, viral load in the three untreated and the
four historic control macaques peaked at 2 wpi, and was one
log lower though these animals had received higher inoculum
doses. Mean peak (2–3 wpi), acute (1–4 wpi) and post-acute
(5–9 wpi) viremia were comparable among the Depo-naive
animals in group A (n = 3) and historic controls (n = 4), but
were also comparable among the Depo-treated macaques in
groups B, C and D (n = 9 total) in spite of the fact that they
were inoculated with different virus titers (Table 1). When
compared as groups of Depo-naive (n = 7) vs. Depo-treated
(n = 9) macaques, results showed that the mean peak as well
as acute (P = 0.038 and 0.031, respectively), but not post-
acute viremia (P = 0.424) was significantly higher in the
Depo-treated animals (Table 1). A drop in peripheral CD4+ T
cells accompanied the rise in viremia in all infected animals
(Fig. 1B). Among the Depo-treated animals, the extent of this
drop appeared to be more modest in those that received
smaller doses of inoculating virus (groups C and D). This
latter observation is consistent with findings made in infection
with the highly pathogenic SHIVDH12R, in which macaques
inoculated intravenously with smaller amounts of viral
inocula suffered a marked but incomplete loss of CD4+ T
cells despite peak plasma viral RNA levels that were
comparable to those receiving higher inocula (Igarashi
Table 1
Comparison of plasma viremia in Depo-naïve (n = 7; group A = 3, historic




Naive RM (±SE) Depo-treated RM (±SE) P
Peak viremia
Mean 6.42 (±0.37) 7.45 (±0.28) 0.038
Historic cohort 6.48 (±0.52) n/a
Group A 6.34 (±0.63) n/a
Group B n/a 7.68 (±0.31)
Group C n/a 7.04 (±0.59)
Group D n/a 7.62 (±0.58)
Acute (week 1–4)
Mean 5.94 (±0.34) 6.95 (±0.26) 0.031
Historic cohort 5.97 (±0.50) n/a
Group A 5.90 (±0.55) n/a
Group B n/a 7.21 (±0.29)
Group C n/a 6.55 (±0.54)
Group D n/a 7.09 (±0.57)
Post-acute (week 5–9)
Mean 4.93 (±0.20) 4.74 (±0.13) 0.424
Historic cohort 5.07 (±0.30) n/a
Group A 4.73 (±0.25) n/a
Group B n/a 4.69 (±0.06)
Group C n/a 4.38 (±0.19)
Group D n/a 5.15 (±0.07)
RM, rhesus macaques; SE, standard error; n/a, not applicable. P values were
estimated using unpaired t tests. Note that the difference in mean peak and acute
viremia between Depo-naïve (n = 7) and Depo-treated (n = 9) animals was
significant (P < 0.05).
Fig. 1. Mean plasma viral load and CD4+ T cell counts in Depo-Provera treated
(Groups B, C and D) and untreated (Group A, Historic cohort) IVAG inoculated
macaques. Data are the geometric mean values obtained from the three animals
in Groups A–D, and of the four animals in the historic cohort.
Fig. 2. V3–V5 envelope variants present in week 2 PBMC of Depo-Provera
treated and untreated IVAG-inoculated macaques. Envelope variants were
analyzed in PBMCs collected at the first virus-positive time point (week 2 post-
infection) and HMA profiles are shown. Lane 1, AK78; lane 2, R457; lane 3,
R946; lane 4, P289; lane 5, P460; lane 6, R902; lane 7, AP42; lane 8, M035; lane
9, T226; lane 10, AK04; lane 11, BA05; lane 12, L574.
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viremia is one order of magnitude higher in Depo-treated
compared to untreated macaques.
Depo-Provera facilities the transmission of multiple variants
We next examined the complexity of proviral DNA present
in PBMCs of Depo-naive and Depo-treated macaques by
HMA (Delwart et al., 1994). Proviral DNA, rather than
plasma RNA, was analyzed to obtain precise information
about the history of the transmitted viruses, including
archived proviruses in addition to the contemporary predom-
inant variant(s). A restricted, but different HMA pattern was
found in the Depo-naive macaques (Group A, Fig. 2),
consistent with the notion that a specific viral variant is not
consistently transmitted by IVAG inoculations (Greenier et al.,
2001). In contrast, a more diverse pattern was seen in the
Depo-treated macaques, with multiple bands present in all
three monkeys in Group B and two of three macaques in
Group C. The complexity of the transmitted virus, however,
appeared to decrease in animals that received the lowest
inoculum dose, with multiple bands seen only in macaque
AK04 of group D (lane 10, Fig. 2). A more diverse HMA
pattern observed in those Depo-treated animals that received
higher inoculum doses (groups B and C) suggests the
transmission of more variants and/or a more rapid diversifi-
cation in the new host.Depo-Provera alters the relative proportions of circulating X4
and R5 SHIVs in dually infected macaques
We previously reported R5 dominance in macaques dually
infected with X4-SHIVSF33A and R5-SHIVSF162P3 (Harouse et
al., 2003). To assess whether hormonal treatment influences the
relative replication of the two co-infecting viruses, the genotype
of the circulating virus was determined (Table 2). All animals,
with the exception of BA05 in group D, were dually infected.
Consistent with previous observations (historic cohort), R5
Table 2




Group A Group B Group C Group D Historic cohort
AK78 R457 R946 P289 P460 R902 AP42 M035 T226 AK04 BA05 L574 AH42 A179 AJ12 AK89
2 80 4 0 5 8 0 1 0 93 33 0 100 58 5 10 10
3 4 0 5 100 100 95 0 76 100 93 0 38 4 0 7 ND
5 28 0 0 75 9 0 0 71 79 41 0 2 ND ND 1 13
7 21 0 0 37 15 33 2 66 94 54 0 16 7 50 ND ND
9 13 4 18 34 27 29 2 100 62 41 0 14 1 55 1 ND
12 9 0 0 100 59 76 100 100 76 39 0 0 0 ND ND 10
Differential PCR was employed to determine the percentage of X4 and R5 virus in plasma. Numbers indicate the percentage for the X4 virus in Depo-naive (Group A
and historic cohort) and Depo-treated (Groups B, C and D) animals at various times post-infection. ND, not determined.
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macaques. In macaques R457 and R946, R5 dominance
occurred early and persisted throughout the period of study.
For AK78, the majority of circulating virus at the first time point
sampled (week 2) was of the X4 genotype. By 3wpi, however,
the R5 virus outgrew and remained dominant. In stark contrast,
although >90% of the circulating virus of the Depo-treated
macaques receiving the highest inoculum dose (group B) at
week 2 was of the R5 genotype, this was replaced by the X4
virus at 3 wpi. The X4 virus load in these animals fluctuated
thereafter, but was sustained and was higher than those seen in
the Depo-naive group. Similar observations were made in
Depo-treated macaques that received 500 TCID50 of the mixed
inoculum (Group C). X4 virus loads were high and persisted inFig. 3. Plasma anti-simian immunodeficiency virus (SIV) binding antibody titers after
Depo-naive (Group A, open symbols; historic cohort, grey symbols) and Depo-treatmacaques M035 and T226, but remained low in AP42 until
12 wpi. For animals receiving the 100 TCID50 dose (Group D),
however, X4 virus replication was present in AK04 at levels that
were comparable to the R5 virus, but was lower in L574 and
undetectable in BA05. Thus, similar to the transmission of viral
variants (Fig. 2), there appears to be a dose-dependency in X4
representation in the Depo-treated dually infected macaques.
Nevertheless, an overall comparison of the genotypic data in
Depo-naive (Group A and historic cohort) and Depo-treated
(groups B to D) animals suggested a trend towards X4
dominance in dually infected macaques that received prior
treatment with Depo-Provera, with 1/7 vs. 6/9 Depo-naive and
Depo-treated animals respectively showing X4 dominance at 9–
12 wpi (P = 0.06, Fisher's exact test). A more significantIVAG inoculation with mixed inocula of X4-SHIVSF33A and R5-SHIVSF162P3 in
ed (Groups B–D) macaques.
Table 3
Comparison of anti-SIV antibody (A) and IFN-γ (B) responding animals in the
Depo-naive (n = 6) and Depo-treated (n = 9) cohorts
A: α-SIV antibodies
Week 4 (%) Week 7 (%) Week 12 (%)
Naïve (n = 6) 5 (83) 6 (100) 5 (83)
Depo-treated (n = 9) 3 (33) 9 (100) 9 (100)
P 0.119 N/A 0.400
B: IFN-γ-secreting T cells
Week 1–4 (%) Week 5–9 (%) Week 12 (%)
Naive (n = 6) 6 (100) 6 (100) 5 (83)
Depo-treated (n = 9) 0 (0) 7 (78) 9 (100)
P <0.001 0.486 0.400
Comparisons were made by calculating the number of animals within the Depo-
naive and Depo-treated groups that showed (A) anti-SIV binding antibody titers
or (B) SIV gag-specific IFN-γ-secreting T cells at the indicated times post-
infection. P values were calculated using Fisher's exact tests.
173N. Trunova et al. / Virology 352 (2006) 169–177difference was obtained when X4 genotype data in Depo-naive
(1/7) were compared to those of Depo-treated animals in groups
B and C only (6/6) (P = 0.0047, Fisher's exact test).
Furthermore, replacement of R5 with X4 virus in the Depo-
treated macaques occurred at or after 3 weeks of infection, a
finding which supports an immune- rather than a transmission-
based mechanism.
Slower rates of antiviral cellular immune response in
macaques treated with Depo-Provera
To examine whether Depo-Provera treatment altered the
development of antiviral immune responses in the duallyFig. 4. Anti-simian immunodeficiency virus (SIV) Gag interferon (IFN)-γ-secreting T
dually infected macaques (Group A, open symbols; historic cohort, grey symbols) and
D) TCID50 mixed inocula of X4-SHIVSF33A and R5-SHIVSF162P3. Values shown arinfected macaques and, consequently, the composition of the
replicating virus, plasma anti-SIV antibodies and SIV Gag-
specific IFN-γ responses in PBMCs were determined. With
the exception of AK78, all the infected macaques developed
anti-SIV binding antibodies by 6 weeks post-infection (Fig. 3),
with increasing titers over the 12 week study period. Although
the magnitude of the antibody response varied among the
infected macaques, no significant difference in the rates of this
response was seen between the Depo-naive and Depo-treated
macaques (Fig. 5A). Anti-SIV binding antibodies could be
detected at 4 wpi in both groups of animals, with similar
numbers of animals responding (Table 3; P = 0.119, Fisher's
exact test), suggesting that progesterone treatment does not
have an effect on the response rate or tempo of development
of antiviral antibodies.
PBMCs from dually infected macaques were then exam-
ined for their ability to secrete IFN-γ in response to
stimulation with SIV-Gag peptides (Fig. 4). Results showed
that Gag-specific IFN-γ-secreting T cells could be detected in
macaques R457 and R946 in the Depo-naive group and the
four animals in the historic cohort group within the first 3
weeks of infection, and the response remained detectable for
the 12 weeks of study. The exception was AK78, the monkey
that did not seroconvert. AK78 did not respond with IFN-γ
secretion to in vitro SIV-Gag peptide stimulation at any of the
time points tested. The ELISPOT response was particularly
robust in macaque R457, with high numbers of spot forming
cells present at 1 week post-infection. In contrast, irrespective
of inoculum dose, IFN-γ-secreting T cells were not detected
until 5 wpi in the Depo-treated animals, with one of three
animals in group B and two of three animals each in groups C
and D responded at this later time point. The number ofcell frequencies in peripheral blood mononuclear cells (PBMCS) of Depo-naïve
Depo-treated animals receiving 2500 (Group B), 500 (Group C) and 100 (Group
e the average of at least two independent assays.
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levels that were superior to those seen in the Depo-naive
animals by 9–12 wpi but comparable to those observed at
week 3–5. A comparison of the mean ELISPOT responses in
the Depo-naive and Depo-treated macaques at various times
post-inoculation showed that the response of IFN-γ production
to viral peptide stimulation is indeed delayed with Depo-
Provera treatment (Fig. 5B). The mean number of IFN-γ-
secreting cells for animals in the Depo-naive group was
significantly higher during the peak (week 1–2) and acute
(week 3–5) phase of infection (P = 0.0002 and 0.033,
respectively), even when data from the outlier R457 were
excluded from the analysis (P = 0.0005 for w1–2). Further,
these cells could be detected in all Depo-naive animals during
the acute infection, but in none of the Depo-treated animals
until 5 wpi (Table 3; P = < 0.001, Fisher's exact tests). Thus,
progesterone treatment impacts on the development of anti-
SIV IFN-γ but not antibody response.Fig. 5. Comparison of anti-simian immunodeficiency virus (SIV) binding
antibody titers (A) and ELISPOT responses (B) in Depo-naïve and Depo-treated
macaques. The mean antibody titers and number of spot forming cell (SFC)/106
cells (B) for each animal in the Depo-naive (n = 6, black bars) and Depo-treated
(n = 9, open bars) group were log10-transformed and plotted. Note that RM
AK78 (Depo-naive group) was excluded from the analysis since it did not
seroconvert. Error bars represent standard errors (SE) and P values were
estimated using unpaired t tests.Discussion
In this study, we found different virologic and immunologic
outcome of acute infection in Depo-Provera naive and treated
macaques vaginally inoculated with a mixture of X4 and R5
SHIVs. In agreement with previous reports in HIV-1 infected
women (Lavreys et al., 2004a; Sagar et al., 2004) and in SIV-
infected macaques (Abel et al., 2004; Marx et al., 1996),
increased susceptibility and enhanced viral burden that were
accompanied by greater genetic complexity of the transmitted
viral population were seen in dually infected macaques
administered the injectable hormonal contraceptive prior to
virus inoculation. Furthermore, X4 virus replication was overly
represented and the development of an antiviral cellular
immune response was delayed in dually infected macaques
that received Depo-Provera. Since CXCR4-using viruses are
usually more cytopathic and replicate more efficiently, their
dominance might exacerbate progression to disease (Berger et
al., 1999).
Increase in viral load and susceptibility of the host
observed with hormonal contraceptive treatment in SIV-
infected macaques had been attributed to the thinning of the
vaginal epithelium (Abel et al., 2004; Marx et al., 1996). If
this was indeed the case, we would have expected to see viral
load differences very early on in the infection process.
However, the differences in plasma viremia in the Depo-naive
and Depo-treated dually infected macaques were not apparent
until 2–3 wpi, with virus replication reaching its peak in the
Depo-naive monkeys at 2 wpi, but continued unchecked for
another week in the Depo-treated animals, peaking at 3 wpi
(Fig. 1A). Furthermore, the difference in X4 dominance we
observed between the two groups of animals was also a late
event, occurring at 3 wpi and later. Collectively, the data
argue for an immune- rather than a transmission-based
mechanism for these virologic effects seen associated with
Depo-Provera use. The fact that women on oral contraceptives
where thinning of the vaginal epithelium had not been firmly
established are also at increased risks of HIV-1 infection
(Bahamondes et al., 2000; Guimaraes et al., 1995; Lavreys et
al., 2004b; Martin et al., 1998; Mauck et al., 1999; Miller et
al., 2000; Ungchusak et al., 1996; Wang et al., 1999) lends
further support to this argument for a role of immunological
factors.
We previously hypothesized, based on CD8+ T cell
depletion experiments in dually infected macaques, that X4
virus replication is more susceptible to control by CD8-
mediated anti-viral immune responses (Harouse et al., 2003).
In this regard, our finding that X4 virus dominance was
associated with a delay in IFN-γ antiviral immune responses
in the dually infected Depo-treated animals is of interest. In
rhesus macaques, serum levels of medroxyprogesterone
(MPA) increased within 24 h following administration of a
single intramuscular injection of 30 mg Depo-Provera, and
were maximal on day 14 and undetectable by day 70 (Hild-
Petito et al., 1998). Thus, the increase in acute (week 1–4)
but not post-acute (week 5–9) viremia (Fig. 1, Table 1) (Abel
et al., 2004; Marx et al., 1996), and the delay of 3–5 weeks
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and 5) seen here in macaques that were Depo-treated 4–
5 weeks prior to challenge correspond well with the 10-week
duration of MPA circulation to be expected in these animals.
We propose, therefore, that the immunosuppressive effects of
Depo-Provera on the development of antiviral cellular
immune response account for the increase in virus replication
and X4 virus dominance in the progestin-treated dually
infected animals. This attenuation of antiviral cellular immune
response with Depo-Provera use can also explain for the
presence of multiple viral variants in Depo-treated macaques
(Fig. 2), since absence of selective immune pressures would
allow for greater replication and hence, diversification of the
transmitted virus in the new host. Studies using larger cohorts
of animals will be required to firmly establish correlations
between these virologic and immunologic findings and Depo-
Provera treatment.
Increased virus susceptibility, enhanced acute viremia and
delay in the development of antiviral cellular responses were
seen in all Depo-treated macaques irrespective of the innoculum
dose (Tables 1 and 3, Fig. 5). Furthermore, progestin treatment
abrogated the dose-dependency in peak viremia reported for
SIV and SHIV following mucosal infections (Fig. 1A) (Endo et
al., 2000; Hirsch and Johnson, 1994; Miller et al., 1994; Trivedi
et al., 1994). However, there appeared to be a dose-dependent
effect on the complexity as well as the efficiency of X4 virus
transmission, with decreased complexity and X4 representation
in animals receiving the lowest inoculum dose (group D) (Fig.
2, Table 2). We attribute these latter findings of dose-
dependency to the stochastic nature of SIV/SHIV vaginal
transmission (Enose et al., 1998; Greenier et al., 2001; Neildez
et al., 1998), which is likely to have a greater impact when the
complexity of the quasi-species in the inocula is reduced, as is
the case of low inoculum.
In summary, our data strongly suggest a role of progestin-
containing contraceptive use, such as Depo-Provera, in
increasing susceptibility to vaginal SHIV transmission and
suppressing the development of an antiviral cell-mediated
immune response. Heterosexual transmission accounts for the
majority of new HIV infections worldwide and factors that
enhance viral transmission and/or replication will likely raise
the bar for microbicide or vaccine efficacy. The enhancing
effects reported here associated with progestin-based hor-
monal use on viral replication should therefore be taken into
consideration in the design and evaluation of preventive
strategies for HIV transmission in women. It would also be
useful to determine to what extent sustained progestin-only
contraceptive use, such as Norplant, increases the risk of
infection in HIV-1 negative women and impacts on the
antiviral immune response in HIV-infected women. Lastly,
since Depo-Provera administration prior to intravaginal
SIVmac239 challenge has been reported to abrogate
attenuated lentivirus-induced protection (Abel et al., 2004),
it will be important to evaluate possible effects of progestin-
based contraceptives in diminishing vaccine efficacy by
delaying the development of an anamnestic immune
response.Materials and methods
Virus and animal inoculations
Stocks of X4-SHIVSF33A and R5-SHIVSF162P3 were
propagated and titrated in a CEMX174.CCR5 cell line. The
titer of both viruses is 5.9 × 103 TCID50/ml. All infections
were carried out with female RM (Macaca mulatta) individ-
ually housed at the Tulane National Primate Research Center
in compliance with the Guide for the Care and Use of
Laboratory Animals. Animals were not experimentally cycled
and were confirmed to be serologically negative for simian
type D retrovirus, SIV and simian T-cell lymphotropic virus
before use. A single intramuscular dose of 30 mg Depo-
Provera, a dose that is comparable to that administered to
women for contraceptive purposes, was administered to some
macaques 4 to 5 weeks prior to intravaginal (IVAG)
inoculation. Following infection, whole blood was collected
at weekly intervals. Plasma virus was quantified by an SIV-
specific branched DNA (bDNA) signal amplification assay
(Bayer Diagnostics, Emeryville, CA) and T cell subsets were
determined by Trucount flow cytometry analysis (Becton
Dickinson, San Jose, CA).
Heteroduplex mobility assay (HMA)
A 648-bp fragment encompassing the V3–V5 region of
gp120 was amplified from PBMC DNA using the ED5/ED12
and the ED7/ED8 primers in a nested PCR reaction as
previously described (Delwart et al., 1994). A corresponding
fragment was also prepared from the reference HIV-1SF128A
plasmid DNA. An excess amount of the HIV-1SF128A
amplified fragment was then mixed with the PCR products
to promote heteroduplex formation. Samples were run on
nondenaturing 5% polyacrylamide gels and stained with
ethidium bromide.
Virus genotype
The relative proportion of replicating X4 and R5 virus in
the plasma of dually infected macaques was determined by
real-time PCR that distinguishes the two viruses (Boadi et al.,
2005). Briefly, viral RNA was extracted from plasma, reversed
transcribed and amplified with the conserved ED5/ED12
primers. Ten-fold dilutions of the first round PCR products
were then subjected to separate X4- and R5-specific real-time
PCR reactions. Standard curves were generated in parallel with
serial 10-fold dilutions of a known quantity of the X4 or R5
reference strain plasmid. Copy numbers of X4-SHVSF33A and
R5-SHIVSF162P3 sequences were calculated from the standard
curves and expressed as relative percentages.
Anti-SIV antibody titers and IFN-γ response to SIVmac239
Gag
Serum anti-SIV antibody titers were measured as previously
described (Lu et al., 1998), and results are reported as dilutions
176 N. Trunova et al. / Virology 352 (2006) 169–177that produced optical density values above the cutoff value.
For measuring interferon-γ production in PBMCs, 105
lymphocytes in triplicates were pulsed with peptides spanning
the entire coding region of SIVmac239 Gag (obtained through
the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH). The lymphocyte/peptide
mixtures were cultured in each well of a mouse anti-human
IFN-γ antibody (clone B27; Pharmingen, San Diego, CA)
coated 96-well plate for 18–24 h at 37 °C. Biotinylated anti-
human IFN-γ antibody (clone 7-B6-1; Mabtech USA,
Mariemont, OH) followed by avidin-conjugated with horse-
radish peroxidase was then added. Spots were developed with
the addition of chromogen-substrate and counted in an
ImmunoSpot reader. Controls include cells cultured in medium
alone (negative) or stimulated with staphylococcal enterotoxin
B (10 μg/ml) (positive). Responses are considered positive
when the frequency of IFN-γ secreting cells exceeds the mean
spot-forming cell (SFC) count of the negative controls plus
twice the standard deviation. For data reporting, the numbers
of SFC observed in medium-only wells were subtracted from
the numbers of SIV peptide-stimulated wells.
Data analysis
Arithmetic means of log10 viral RNA values at peak, acute
(week 1–4) and post-acute (week 5–9) infection shown in Table
1 were compared using unpaired t tests. Statistical analysis was
performed using GraphPad Prism Version 3.03 for Windows.
P values of <0.05 were considered significant.
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